anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention relates to a process for the preparation of compounds for the treatment of AIDS, herpes and other viral infections by means of lipid derivatives of antiviral agents. The compounds comprise nucleoside analogues having antiviral activity which are bound generally by means of a phosphate group in the 5' position of the pentose residue to a group selected from lipids. The process comprises the step of reacting an antiviral nucleoside having a hydroxylribose group with a phospholipid in the presence of a coupling reagent, as a result of which the said nucleoside is bound to the said phospholipid by a phosphate bond in the position of the said hydroxylribose group comprising a nucleoside analogue having a base portion corresponding to a purine or pyrimidine or its analogue and a sugar portion comprising a pentose residue, in which at least one of the said portions is a nucleoside component which does not occur naturally, and a lipid portion bound to the said pentose residue, with the condition that the said compound is in the form of a liposome when the said pentose residue is arabinose and the said base portion is cytosine or adenine. The lipophilic nature of these compounds provides advantages over use of the nucleoside analogue alone. It is also possible to incorporate them into the lamellar structure of liposomes, either alone or in combination with similar molecules. In the form of liposomes these antiviral agents are preferentially retained by macrophages and monocytes, cells which have been shown to anchor to the target HIV virus. The specificity of an additional site can be incorporated into the liposomes with the addition of ligands, such as monoclonal antibodies or other peptides or proteins which bind to viral proteins. Effective nucleoside analogues are dideoxynucleosides, azidothymine (AZT) and aciclovir; lipid groups may be glycolipids, sphingolipids, phospholipids or fatty acids. After intracellular hydrolysis the compounds continue to have non- phosphorylated antiviral nucleosides. The compounds are effective in improving the efficacy of antiviral nucleoside analogues in prolonging antiviral activity after drug administration has ceased, and in the presence of retroviral replication in HIV infections which become resistant to treatment with conventional forms of anti- retroviral agents.
Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.
The invention provides siRNA targeting AGT gene expression, and belongs to the technical field of biological medicines. The invention specifically provides an siRNA and an siRNA conjugate for inhibiting AGT gene expression, wherein the siRNA comprises a sense strand and an antisense strand; wherein the antisense strand comprises at least 17 consecutive nucleotides differing by NO more than 4 nucleotides from the nucleotide sequence shown in any one of SEQ ID NO. 2-SEQ ID NO. 70 or SEQ ID NO. 256-SEQ ID NO. 260; the antisense strand is 17-30 nucleotides in length; the sense strand is 17-30 nucleotides in length and is at least partially complementary to the antisense strand. The siRNA and the siRNA conjugate provided by the invention have good stability, excellent AGT gene inhibition activity, satisfactory cytotoxicity and immunostimulation, can obviously reduce the concentration of AGT protein at animal level, inhibit RAS (advanced cancer) pathway from source, and are used for treating/preventing related diseases caused by the RAS pathway, such as hypertension, and also comprises refractory hypertension and uncontrollable hypertension.
Patients were randomized to recieve "individual" (50, 75 or 100 IU/day) or "standard" (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64).
<P>PROBLEM TO BE SOLVED: To inexpensively provide a large amount of antioxidant, an aging prevention and/or an anticancer agent, preventing lesion by oxidation and aging of a muscle cell and a cerebral tissue based on activities of an antioxidative peptide by paying attention to the antioxidative ability of an antioxidative peptide, e.g. carnosine and anserine.  <P>SOLUTION: The antioxidant, the aging prevention and/or the anticancer agent contains the antioxidative peptide in combination with a simultaneously ingested antioxidative vitamin. The antioxidant, the aging prevention and/or the anticancer agent is obtained by using an extracted liquid or extracted powder of a livestock product containing the carnosine and the anserine as a source of supply of the carnosine and the anserine, or an obtained preparation of the carnosine and the anserine. The functional food or drink containing the antioxidative peptide as an active ingredient is also provided.  <P>COPYRIGHT: (C)2003,JPO
The invention discloses heat-clearing and detoxicating preparations for patients suffering from sphagitis. The heat-clearing and detoxicating preparations are prepared by the following bulk medicines in part by mass: 13-18 parts of platycodon grandiflorum, 8-14 parts of liquorice, 8-16 parts of veitch gentian herb with roots, 10-15 parts of edible debregeasia roots and leaves, 10-16 parts of henry hemsleya roots, 12-16 parts of honeysuckle, 9-17 parts of tenacious condorvine stem roots and leaves, 10-15 parts of dogwood, 12-19 parts of smallflower galinsoga herb, 9-13 parts of roots of large-flowered skullcap, 15-19 parts of pinkflower ecdysanthera roots and leaves, 10-16 parts of aster, 11-16 parts of veronicastrum herb, 11-17 parts of mulberry leaves, 13-18 parts of fringed iris herb and 12-17 parts of centaury. The heat-clearing and detoxicating preparations are prepared by natural bulk traditional Chinese medicines, do not have any toxic or side effects, and are high in safety. The composition of the heat-clearing and detoxicating preparations is completely in conformity with the principle of traditional Chinese medicines and mind and body features of the patients suffering from sphagitis. The heat-clearing and detoxicating preparations have effects of clearing heat and eliminating phlegm, diminishing inflammation and stopping pain, draining water and diminishing swelling. According to clinical verifications, the heat-clearing and detoxicating preparations have a notable curative effect on acute laryngopharyngitis and chronic pharyngolaryngitis, improper symptoms and signs of throats of the patients can be improved effectively, and an effect of preventing relapse is achieved.
BACKGROUND: Extrahepatic manifestations in patients with primary biliary cholangitis (PBC) are frequently observed recently. We aimed in this study to explore the clinicopathological characteristics and prognosis of glomerulonephritis in patients with PBC.
METHODS: Consecutive PBC patients admitted to Peking Union Medical College Hospital from January 2002 to May 2019 were retrospectively enrolled. PBC patients with other autoimmune diseases which may have nephritis were excluded. Structured interview, systemic rheumatologic examination, and laboratory tests were conducted for each patient. Literature about patients with PBC and glomerulonephritis was reviewed and summarized.
RESULTS: Among the 330 PBC patients enrolled, glomerulonephritis were identified in 10 patients (3.0%). Eight (80.0%) were females and 2 (20.0%) were males. The mean age was 58.4 ± 9.5 years old. Membranous nephropathy (MN) was revealed in 4 patients, IgA nephropathy (IgA N) in 2 patients, minimal change disease (MCD) in 2 patients, mesangial proliferative glomerulonephritis in 1 patient, and renal amyloidosis in 1 patient. Compared to the literature reviewed, 10 cases of MN, 1 case of MCD, 1 case of IgA N, and 1 case of acute poststreptococcal glomerulonephritis (APSGN) were observed.
CONCLUSIONS: Glomerulonephritis may not be a well-recognized feature of PBC and is not a rare complication and deserved to be routinely screened in clinical practice. As MN is the most common form of glomerulonephritis in PBC patients and PBC can be asymptomatic at an early stage, patients presented with MN should be screened for PBC, so to avoid cirrhosis. Key Points • Patients with primary biliary cholangitis (PBC) can be complicated with glomerulonephritis, and membranous nephropathy (MN) is the most common form.
Introgression of resistance genes from wild or related species is a common strategy to improve disease resistance of wheat cultivars. Pm17 is a gene that confers powdery mildew resistance in wheat. It encodes an NLR type of immune receptor and was introgressed from rye to wheat as part of the 1RS chromosome arm translocation several decades ago. So far it has not been possible to separate Pm17 from its co-introgressed rye genes due to suppressed recombination. Here we tested in the field transgenic Bobwhite wheat overexpressing Pm17 without any other rye genes. Four transgenic events showed high levels of PM17 protein accumulation, strong powdery mildew resistance, and no pleiotropic effects during three field seasons. We used a combined approach of transgene insertion and cross-breeding to generate lines co-expressing Pm17 and Pm3, or Pm17 and Pm8. Blumeria graminis f. sp. tritici infection tests confirmed additive, race-specific resistance of the two pyramided transgenes in lines Pm17+Pm3b and Pm17+Pm8. Furthermore, pyramided lines showed strong powdery mildew resistance during three field seasons. We conclude that the combination of overexpressed NLR genes from the extended gene pool broadens and diversifies wheat disease resistance.
There is a growing body of evidence suggesting that water temperature can significantly impact the dietary fatty acid requirements of Nile tilapia (Oreochromis niloticus). Therefore, this study assessed the effectiveness of different dietary lipid sources on the growth performance of Nile tilapia reared at suboptimal temperatures. A network meta-analysis was performed, including searches of PubMed and Scopus from inception to January 2022, for trials that evaluated the effects of lipid sources on cold-stressed Nile tilapia. The Bayesian hierarchical framework was used to pool and compare the effect sizes of growth parameters such as weight gain, feed intake, and feed conversion ratio (FCR). Furthermore, the surface under the cumulative ranking curve (SUCRA) was obtained to calculate the probability that each lipid source was the most effective against cold stress. All subsequent numbers refer to comparisons with diets containing only fish oil. Dietary Aurantiochytrium significantly increased weight gain (SMD = 2.00, CrI: 0.70 to 3.40). In contrast, diets containing coconut oil led to significantly lower weight gain (SMD = - 3.30, CrI: - 6.00 to - 0.63) and higher FCR (SMD = 17.0, CrI: 6.70 to 27.0). Additionally, dietary corn oil was associated with a decrease in feed intake (SMD = - 2.32, CrI: - 3.91 to - 0.80), while a combination of fish and corn oil reduced FCR (SMD = - 5.70, CrI: - 11.0 to - 0.81). In general, the analysis of SUCRA values revealed that in cold-stressed Nile tilapia, Aurantiochytrium, sunflower oil, and the combination of fish and corn oil were the most effective lipid sources for improving growth at suboptimal temperatures. The results of the current study can serve as a basis for future studies that focus on the use of dietary lipid sources to mitigate cold stress in Nile tilapia.
FIELD: medicine, oncology, biochemistry, pharmacy. SUBSTANCE: invention relates to medicinal preparations, in particular, retroviral vectors transducing cytochrome P-450. Invention involves pharmaceutical composition for carrying out an anti-tumor therapy and representing capsule, encapsulating cell comprising gene that expresses cytochrome P-450. Capsule comprises porous membrane that is permeable for prodrug molecules that is activated with cytochrome P-450 and converted to an active metabolite. The advantage of invention is the development of new replicatively defective retroviral vectors carrying gene encoding cytochrome P-450. EFFECT: valuable properties of vectors. 7 cl, 5 ex
After providing consent, participants will complete web-based baseline EpiNP survey. All respondents who report greater than equal to (≥)2 voids/night, and a randomly selected cohort of respondents reporting 0 and 1 void/night will use the EpiNP 3-day web-based bladder diary.
The present invention is directed to an apparatus for formulating a custom mixed cosmetic product at the point of sale in response to specific input criteria. The apparatus includes a plurality of containers (12) for storing a plurality of cosmetically functional mixtures. The cosmetically functional mixtures are adapated to combine to form a cosmetic product. An input means (14) is provided for entering into a computer (16) the specific input criteria that is representative of a customer's need. The computer outputs a series of instruction sets in response to the specific input criteria to a dispensing means (18). The dispensing means automatically and sequentially dispenses the plurality of cosmetically functional mixtures into a formulation receptacle (20) in response to the instruction sets. The plurality Of cosmetically functional mixtures combine in the recepatcle (20) to form a custom mixed formulation of cosmetic product at the point of sale.
Lateral epicondylitis is a soft-tissue lesion of the tendinous origin of the wrist extensor muscles at their origin on the lateral humeral epicondyle. The extensor carpi radialis brevis is the area of most pathologic changes. It begins as a microtear of the tendinous origin of the wrist extensor muscles and results in degeneration and reactive granulation tissue formation. Activities involving prolonged or repeated gripping, wrist extension, forearm supination, and pronation cause eventual failure of the affected portion of the tendon. The mechanical failure of the tendon results in an ensuring tendinitis and symptoms of lateral epicondylitis. It is aggravated with movements of the wrist, by palpation of the lateral side of elbow, or by contraction of extensor muscles of the wrist.

There are different treatment methods for lateral epicondylitis. Initially, lateral epicondylitis has been treated with ice, rest, counterforce tennis brace and/or non-steroidal anti-inflammatory drugs. But when the condition is not responding to initial treatment physical therapy is initiated
Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
Background: Sodium‒glucose cotransporter-2 (SGLT2) inhibitors offer glycaemic and cardiorenal benefits in the early stage of chronic kidney disease (CKD). However, the use of SGLT2 inhibitors may increase the risk of genitourinary tract infection (GUTI). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may also cause deterioration of kidney function. The long-term follow-up of cardiorenal outcomes and GUTI incidence in patients with advanced CKD receiving SGLT2 inhibitors combined with ACEIs/ARBs should be further investigated. Methods: We analysed data from 5,503 patients in Taiwan's Taipei Medical University Research Database (2016-2020) who were part of a pre-end-stage renal disease (ESRD) program (CKD stages 3-5) and received ACEIs/ARBs. SGLT2 inhibitor users were matched 1:4 with nonusers on the basis of sex, CKD, and program entry duration. Results: The final cohort included 205 SGLT2 inhibitor users and 820 nonusers. SGLT2 inhibitor users experienced a significant reduction in ESRD/dialysis risk (aHR = 0.35, 95% CI = 0.190.67), and SGLT2 inhibitor use was not significantly associated with acute kidney injury or acute kidney disease risk. Among SGLT2 inhibitor users, those with a history of cardiovascular disease (CVD) had greater CVD rates. Conversely, those without a CVD history had lower rates of congestive heart failure, arrhythmia, acute pulmonary oedema, and acute myocardial infarction, although the differences were not statistically significant. Notably, SGLT2 inhibitor usage was associated with a greater GUTI incidence (aHR = 1.78, 95% CI = 1.122.84) shortly after initiation, irrespective of prior GUTI history status. Conclusion: Among patients with CKD stages 3-5, SGLT2 inhibitor use was linked to increased GUTI incidence, but it also significantly reduced the ESRD/dialysis risk without an episodic AKI or AKD risk. Clinical physicians should consider a personalized medicine approach by balancing GUTI episodes and cardiorenal outcomes for advanced CKD patients receiving SGLT2 inhibitors.
Pet obesity is still a major health issue, which is considered an epidemic by some researchers. Prevention is one of the cornerstones of veterinary care, emphasizing the importance of proactive measures. Human lifestyle was affected during the COVID-19 pandemic, resulting in an increased overweight prevalence in the population. The prevalence of overweight and obesity in dogs during this period has been poorly explored. This study's objectives were to assess the percentage of the French dog population with overweight and obesity, compare the results with a study conducted before the COVID-19 pandemic, and investigate any potential changes in the risk factors. The study collected data through a survey completed by dog owners during their pets' vaccination visits at university veterinary hospitals of Maisons-Alfort (Paris) and Toulouse, in France, between 2020 and 2022. The veterinarian recorded the dog's weight and the body condition score using a 9-point scale. The study included a total of 309 dogs. Of these, 1.6 % were underweight, 63.1 % had an ideal body condition, and 35.3 % were overweight, including 2.3 % of all dogs classified as obese. During the pandemic, French dog diets shifted towards increased commercial food consumption and twice-daily feedings compared to a 2003 study. Factors positively associated with overweight were being female (OR = 3.55; 95 % CI: 1.65-8.01; P=0.002), being senior (OR=4.91; 95 % CI: 2.07-12.2; P<0.001) or geriatric (OR=5.81; 95 % CI: 2.04-17.0; P=0.001) and having an owner underestimating dog's body condition (OR=74.1; 95 % CI: 29.8-215; P<0.001). Recognizing the impact of owner perception enables early intervention strategies, such as educating owners during consultations and conducting teaching sessions at the clinic. This proactive approach could contribute to improved health outcomes and help prevent the onset of obesity-related issues in dogs. The new trends in dogs' diets may have global relevance due to the pandemic's widespread impact. Although no immediate impact on overweight is evident, ongoing research is crucial to understand the pandemic's long-term effects.
PROBLEM TO BE SOLVED: To obtain a cerebral function improving agent containing N- acetylneuraminic acid bonded oligosaccharides promoting the metabolism of cerebral phospholipid and gangliosides. SOLUTION: This agent contains the N-acetylneuraminic acid bonded oligosaccharides expressed by the formula (Gal)n-Neu5Ac (Gal is galactose residue; Neu5Ac is N-acetylneuraminic acid residue; (n) is 1 or 2), as the active ingredient. Other suitable conventional ingredients are blended and can be prepared in conventional method. This compound can be used in food and drink such as yogurt, cheese, bread, drinkable beverage, etc. The adult's dosage of the N-acetylneuraminic acid bonded oligosaccharides is at least 10mg/kg per day, preferably 30 to 100mg/kg per day. The N-acetylneuraminic acid bonded oligosaccharides is an oligosaccharides in which galactose is bonded with N- acetylneuraminic acid, obtained by glycosyltransfer reaction of β-galactosidase using lactose and N-acetylneuraminic acid or its salt as the raw material.
This longitudinal study investigated the impact of the first independent steps on harmonic gait development in unilateral cerebral palsy (CP) and typically developing (TD) children. We analysed the gait ratio values (GR) by comparing the duration of stride/stance, stance/swing and swing/double support phases. Our investigation focused on identifying a potential trend towards the golden ratio value of 1.618, which has been observed in the locomotion of healthy adults as a characteristic of harmonic walking. Locomotor ability was assessed in both groups at different developmental stages: before and after the emergence of independent walking. Results revealed that an exponential fit was observed only after the first unsupported steps were taken. TD children achieved harmonic walking within a relatively short period (approximately one month) compared to children with CP, who took about seven months to develop harmonic walking. Converging values for stride/stance and stance/swing gait ratios, averaged on the two legs, closely approached the golden ratio in TD children (R2 = 0.9) with no difference in the analysis of the left vs right leg separately. In contrast, children with CP exhibited a trend for stride/stance and stance/swing (R2 = 0.7), with distinct trends observed for the most affected leg which did not reach the golden ratio value for the stride/stance ratio (GR = 1.5), while the least affected leg exceeded it (GR = 1.7). On the contrary, the opposite trend was observed for the stance/swing ratio. These findings indicate an overall harmonic walking in children with CP despite the presence of asymmetry between the two legs. These results underscore the crucial role of the first independent steps in the progressive development of harmonic gait over time.
Taste-matched placebo. T2D participants will receive placebo between MRI scans.